Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 186.57M | 216.52M | 152.60M | 196.33M | 226.86M |
| Total Receivables | 967.00K | 214.00K | 420.00K | 1.13M | 1.39M |
| Inventory | 2.48M | 1.89M | 2.00M | 3.06M | 4.93M |
| Prepaid Expenses | 2.45M | 2.67M | 4.19M | 5.09M | 6.80M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 1.50M | 2.09M | 1.20M | 1.84M | 2.08M |
| Total Current Assets | 193.96M | 223.39M | 160.40M | 207.45M | 242.06M |
|
|
|||||
| Total Current Assets | 193.96M | 223.39M | 160.40M | 207.45M | 242.06M |
| Net Property, Plant & Equipment | 11.35M | 12.45M | 13.54M | 8.40M | 9.62M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 6.81M | 6.80M | 6.83M | 6.71M | 6.75M |
| Total Assets | 212.12M | 242.64M | 180.77M | 222.56M | 258.42M |
|
|
|||||
| Total Accounts Payable | 16.73M | 17.58M | 14.89M | 13.65M | 17.56M |
| Total Accrued Expenses | 20.04M | 24.09M | 24.25M | 28.61M | 19.32M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 2.17M | 1.97M | 1.60M | 1.84M | 2.17M |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 38.94M | 43.64M | 40.73M | 44.10M | 39.05M |
|
|
|||||
| Total Current Liabilities | 38.94M | 43.64M | 40.73M | 44.10M | 39.05M |
| Long-Term Debt | 99.28M | 98.65M | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 5.34M | 5.90M | 6.45M | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 143.56M | 148.20M | 47.18M | 44.10M | 39.05M |
|
|
|||||
| Common Stock & APIC | 246.66M | 243.89M | 239.72M | 236.73M | 233.77M |
| Retained Earnings | -178.10M | -149.44M | -106.13M | -58.27M | -14.40M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 68.56M | 94.44M | 133.58M | 178.47M | 219.37M |
|
|
|||||